Answers are grounded in this paper and cite their sources.
Marmour et al. [1] have suggested that a low serum thiol level, used as a marker for oxidative stress, can predict mortality risk in HIV-infected injecting drug users. However, they were unable to demonstrate a difference in serum thiol levels between HIV-negative and HIV-positive subjects. Total serum cysteine levels were measured in 71 HIV-seronegative subjects and 92 HIV-positive men according to previously described methods [2], using high performance liquid chromatography and fluorescence detection and by adding monobromobimane. Blood samples were collected between 1989 and 1995 and stored at −20°C, and patients were prospectively followed up for a median of 655 days [interquartile range (IQR), 355–1052 days; range, 1–1996 days]. The median age of the HIV-positive cohort was 38 years (IQR, 32–42 years), 89 (97%) were men, and all men had had sex with men. At the time of blood sample collection, 47 patients in the HIV-positive cohort were asymptomatic, and 45 had one or more AIDS-defining illness; 50 patients had previously taken zidovudine and seven patients had previously taken didanosine as monotherapy, and none of the patients had been treated with combination therapy. The median cysteine level was 240 µmol/l (IQR, 216–262 µmol/l) for HIV-negative subjects, 217 µmol/l (IQR, 196–234 µmol/l) for asymptomatic HIV-positive patients, and 208 µmol/l (IQR, 185–266 µmol/l) for AIDS patients. Both HIV-positive groups had cysteine levels significantly lower than those of normal controls (P < 0.05, Mann-Whitney U test). Survival analysis was performed on HIV-positive patients according to their cysteine levels. Fifty-two patients died during follow-up. Univariate log-rank analysis was used initially to detect significant factors affecting survival: age, AIDS diagnosis, zidovudine, didanosine, and cysteine level (dichotomized at 216 µmol/l, 25th centile of normal controls). Only a history of AIDS (P < 0.001) and a history of having previously taken zidovudine (P = 0.029) showed significant effect on survival. A Cox proportional hazards model was then used for multiple comparison of these factors on survival. AIDS and zidovudine were the only significant independent prognostic factors. By excluding AIDS and zidovudine from consideration in the model, none of the other factors had any significant effect on survival (χ2 = 0.76, P = 0.38, for cysteine). Figure 1 shows the Kaplan–Meier curve of survival probability by cysteine groups (grouped by level above or below 216 µmol/l). We were unable to detect any significant difference between those with high and low cysteine levels.Fig. 1: . Survival by cysteine group.Reports on the changes in blood levels of cysteine in HIV infection have been conflicting [3–5]. We confirm the previously reported low blood cysteine level in HIV-positive patients [3,5]. We also found that low serum level was not associated with shorter survival in this group of HIV-infected predominantly homosexual men and were therefore unable to confirm the results of Marmour et al. [1].
No takes yet. Share an insight, caveat, or question.
Huengsberg et al. (1998) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: